Detalle Publicación


Role of capsule endoscopy in alarm features and non-responsive celiac disease: a European multicenter study

Autores: Perez-Cuadrado-Robles, E. ; Lujan-Sanchis, M. (Autor de correspondencia); Elli, L. ; Juanmartinena-Fernandez, J. F.; Garcia-Lledo, J. ; Ruano-Diaz, L.; Egea-Valenzuela, J.; Jimenez-Garcia, V. A.; Arguelles-Arias, F.; San Juan-Acosta, M. ; Carretero Ribón, Cristina; Alonso-Lazaro, N.; Rosa, B.; Sanchez-Ceballos, F. ; Lopez-Higueras, A.; Fernandez-Urien-Sainz, I. ; Branchi, F. ; Valle-Munoz, J.; Borque-Barrera, P.; González Vázquez, Santiago; Pons-Beltran, V. ; Xavier, S. ; Gonzalez-Suarez, B. ; Herrerias-Gutierrez, J. M. ; Perez-Cuadrado-Martinez, E. ; Sempere-Garcia-Arguelles, J.
Título de la revista: DIGESTIVE ENDOSCOPY
ISSN: 0915-5635
Volumen: 30
Número: 4
Páginas: 461 - 466
Fecha de publicación: 2018
Background and AimThe role of capsule endoscopy (CE) in established celiac disease (CD) remains unclear. Our objective was to analyze the usefulness of CE in the suspicion of complicated CD. MethodsThis was a retrospective multicenter study. One hundred and eighty-nine celiac patients (mean age: 46.616.6, 30.2% males) who underwent CE for alarm symptoms (n=86, 45.5%) or non-responsive CD (n=103, 54.5%) were included. Diagnostic yield (DY), therapeutic impact and safety were analyzed. ResultsCapsule endoscopy was completed in 95.2% of patients (small bowel transit time: 270.5100.2min). Global DY was 67.2%, detecting atrophic mucosa (n=92, 48.7%), ulcerative jejunoileitis (n=21, 11.1%), intestinal lymphoma (n=7, 3.7%) and other enteropathies (n=7, 3.7%, six Crohn's disease cases and one neuroendocrine tumor). The DY of CE was significantly higher in patients presenting with non-responsive disease compared to patients with alarm symptoms (73.8% vs 59.3%, P=0.035). The new findings of the CE modified management in 59.3% of the cases. There were no major complications. ConclusionCapsule endoscopy may be a moderately helpful and safe diagnostic tool in the suspicion of complicated CD, modifying the clinical course of these patients.